Cusp overlap method for self-expanding transcatheter aortic valve replacement.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
01 2024
Historique:
received: 07 08 2023
accepted: 27 10 2023
medline: 4 1 2024
pubmed: 27 11 2023
entrez: 27 11 2023
Statut: ppublish

Résumé

Conduction disturbances and the need for permanent pacemaker (PPM) implantation remains a common complication for transcatheter aortic valve replacement (TAVR), particularly when self-expanding (SE) valves are used. We compared in-hospital and 30-day rates of new PPM implantation between patients undergoing TAVR with SE valves using the conventional three-cusp coplanar implantation technique and the cusp-overlap technique. We retrospectively compared patients without a pre-existing PPM who underwent a TAVR procedure with SE Evolut R or PRO valves using the cusp-overlap technique from July 2018 to September 2020 (n = 519) to patients who underwent TAVR using standard three-cusp technique from April 2016 to March 2017 (n = 128) in two high volume Canadian centers. There was no significant difference in baseline RBBB between the groups (10.4% vs. 13.2; p = 0.35). The rate of in-hospital new complete heart block (9.4% vs. 23.4%; p ≤ 0.001) and PPM implantation (8% vs. 21%; p ≤ 0.001) were significantly reduced when using the cusp-overlap technique. The incidence of new LBBB (30.4% vs. 29%; p = 0.73) was similar. At 30 days, the rates of new complete heart block (11% vs. 23%; p ≤ 0.001) and PPM implantation (10% vs. 21%, p ≤ 0.001) remained significantly lower in the cusp-overlap group, while the rate of new LBBB (35% vs. 30%; p = 0.73) was similar. Cusp-overlap approach offers several potential technical advantages compared to standard three-cusp view, and may result in lower PPM rates in TAVR with SE Evolut valve.

Sections du résumé

BACKGROUND
Conduction disturbances and the need for permanent pacemaker (PPM) implantation remains a common complication for transcatheter aortic valve replacement (TAVR), particularly when self-expanding (SE) valves are used.
AIMS
We compared in-hospital and 30-day rates of new PPM implantation between patients undergoing TAVR with SE valves using the conventional three-cusp coplanar implantation technique and the cusp-overlap technique.
METHODS
We retrospectively compared patients without a pre-existing PPM who underwent a TAVR procedure with SE Evolut R or PRO valves using the cusp-overlap technique from July 2018 to September 2020 (n = 519) to patients who underwent TAVR using standard three-cusp technique from April 2016 to March 2017 (n = 128) in two high volume Canadian centers.
RESULTS
There was no significant difference in baseline RBBB between the groups (10.4% vs. 13.2; p = 0.35). The rate of in-hospital new complete heart block (9.4% vs. 23.4%; p ≤ 0.001) and PPM implantation (8% vs. 21%; p ≤ 0.001) were significantly reduced when using the cusp-overlap technique. The incidence of new LBBB (30.4% vs. 29%; p = 0.73) was similar. At 30 days, the rates of new complete heart block (11% vs. 23%; p ≤ 0.001) and PPM implantation (10% vs. 21%, p ≤ 0.001) remained significantly lower in the cusp-overlap group, while the rate of new LBBB (35% vs. 30%; p = 0.73) was similar.
CONCLUSION
Cusp-overlap approach offers several potential technical advantages compared to standard three-cusp view, and may result in lower PPM rates in TAVR with SE Evolut valve.

Identifiants

pubmed: 38009641
doi: 10.1002/ccd.30910
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

202-208

Informations de copyright

© 2023 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.

Références

Auffret V, Puri R, Urena M, et al. Conduction disturbances after transcatheter aortic valve replacement: current status and future perspectives. Circulation. 2017;136:1049-1069.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706-1715.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705.
Van Gils L, Wöhrle J, Hildick-Smith D, et al. Importance of contrast aortography with lotus transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11:119-128.
Maeno Y, Abramowitz Y, Kawamori H, et al. A highly predictive risk model for pacemaker implantation after TAVR. JJACC Cardiovasc Interv. 2017;10:1139-1147.
Detaint D, Lepage L, Himbert D, et al. Determinants of significant paravalvular regurgitation after transcatheter aortic valve: implantation impact of device and annulus discongruence. JACC Cardiovasc Interv. 2009;2:821-827.
Aljabbary T, Qiu F, Masih S, et al. Association of clinical and economic outcomes with permanent pacemaker implantation after transcatheter aortic valve replacement. JAMA Netw Open. 2018;1(1):e180088. doi:10.1001/jamanetworkopen.2018.0088.
Faroux L, Chen S, Muntané-Carol G, et al. Clinical impact of conduction disturbances in transcatheter aortic valve replacement recipients: a systematic review and meta-analysis. Eur Heart J. 2020;41:2771-2781.
Jilaihawi h, Zhao Z, Du R, et al. Minimizing permanent pacemaker following repositionable self-expanding transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12:1796-1807.
Guetta V, Goldenberg G, Segev A, et al. Predictors and course of high-degree atrioventricular block after transcatheter aortic valve implantation using the CoreValve revalving system. Am J Cardiol. 2011;108:1600-1605.
Lenders GD, Collas V, Hernandez JM, et al. Depth of valve implantation, conduction disturbances and pacemaker implantation with CoreValve and CoreValve Accutrak system for transcatheter aortic valve implantation, a multi-center study. Int J Cardiol. 2014;176:771-775.
Bagur R, Rodés-Cabau J, Gurvitch R, et al. Need for permanent pacemaker as a complication of transcatheter aortic valve implantation and surgical aortic valve replacement in elderly patients with severe aortic stenosis and similar baseline electrocardiographic findings. JACC Cardiovasc Interv. 2012;5:540-551.
Gensas CS, Caixeta A, Siqueira D, et al. Predictors of permanent pacemaker requirement after transcatheter aortic valve implantation: insights from a Brazilian Registry. Int J Cardiol. 2014;175:248-252.
Sammour Y, Krishnaswamy A, Kumar A, et al. Incidence, predictors, and implications of permanent Permanent pacemaker requirement after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2021;14:115-134.
Grubb K. An optimized TAVR care pathway using Evolut PRO and PRO+ early results from the optimize PRO study. Presented at SCAI on April 2021. 2021.
Mendiz OA, Noč M, Fava CM, et al. Impact of cusp-overlap view for TAVR with self-expandable valves on 30-day conduction disturbances. J Interv Cardiol. 2021;2021:1-7.

Auteurs

Talal F Aljabbary (TF)

Schulich Heart Program, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada.
Department of Cardiac Sciences, King Fahad Cardiac Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Ikki Komatsu (I)

Department of Cardiology, Tokyo Medical University Hospital, Tokyo, Japan.

Tomoki Ochiai (T)

Schulich Heart Program, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada.
Department of Cardiology, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan.

Stephen E Fremes (SE)

Schulich Heart Program, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada.

Noman Ali (N)

Division of Cardiology, Terrence Donnelly Heart Center, St. Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada.

Lucas Burke (L)

Division of Cardiology, Terrence Donnelly Heart Center, St. Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada.

Mark D Peterson (MD)

Division of Cardiology, Terrence Donnelly Heart Center, St. Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada.

Neil P Fam (NP)

Division of Cardiology, Terrence Donnelly Heart Center, St. Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada.

Harindra C Wijeysundera (HC)

Schulich Heart Program, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada.

Sam Radhakrishnan (S)

Schulich Heart Program, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH